vTv Therapeutics Inc. (NASDAQ:VTVT) saw a downside of -3.77% to $1.53 after subtracting -$0.06 on Tuesday. The 5-day average trading volume is 1,319,020 shares of the company’s common stock. It has gained $1.6100 in the past week. An average of 4,488,890 shares of the company has been traded in the last 20 days, and the 50-day average volume stands at 2,016,954.
VTVT’s 1-month performance is -11.67% or -$0.2750 on its low of $1.5000 reached on 10/04/21. The company’s shares have touched a 52-week low of $1.44 and high of $4.75, with the stock’s rally to the 52-week high happening on 04/13/21. YTD, VTVT has lost -14.52% or -$0.3350. However, the current price is down -67.79%% from the 52-week high price.
A Backdoor Way To Profit From Today’s Crypto Bull Market
In any crypto bull market, there's a lot of money to be made.
But what if we told you the best opportunities are not cryptocurrencies themselves… but instead, simply crypto stocks?
This strategy is simply and ridiculously easy.
Here are 6 ways to gain exposure to crypto outside the norm. This is arguably the safest bet you can make.
vTv Therapeutics Inc. (VTVT) has a trailing price-to-earnings (P/E) ratio of 34.65 for the broader industry and 32.25 for the sector.VTVT stock has a beta of -1.75. Moving on to other valuation ratios, the trailing price-to-sales (P/S) ratio is 17.34.
vTv Therapeutics Inc.’s quick ratio for the period ended June 29 was 2.20, with the current ratio over the same period at 2.20 meaning that VTVT stock is able to fulfill its debt obligations. The trailing 12-month EBITDA margin is -183.32%. The firm’s gross profit as reported stood at $18.27 million against revenue of $6.41 million.
For the quarterly period ending June 29 this year, vTv Therapeutics Inc.’s cash and short-term investments amounted to $0.12 million against total debt of $0.76 million. Net income and sales went down compared to those figures reported in the previous quarter. Net income grew 100.0% to $10000.0, while revenue of $0.99 million was -9800.0% off the previous quarter. Analysts expected VTVT to announce -$0.07 per share in earnings in its latest quarter, but it posted -$0.01, representing a 85.70% surprise. EBITDA for the quarter stood at more than -$4.65 million. VTVT stock balance sheet for the quarter ending June 29 shows that total liabilities totaled 69.48 million, with total debt at $0.76 million. Shareholders hold equity totaling $83.29 million
Let’s look briefly at vTv Therapeutics Inc. (VTVT) price momentum from a technical analysis perspective. The 9-day relative strength index as at close on 11 October was 36.49% to suggest the stock is trending Neutral, with historical volatility in this time period at 67.58%.
The stock’s 5-day moving average is $1.5710, reflecting a -2.87% or -$0.0450 change from its current price. VTVT is currently trading -12.86% above its 20-day SMA, -40.43% above its 100-day SMA. However, the stock’s current price level is away from the SMA50 and SMA200 by -21.39% and -25.61% respectively.
Stochastic %K and %D was 11.19% and 12.02% and the average true range (ATR) pointed at 0.0941. The RSI (14) points at 37.48%, while the 14-day stochastic is at 3.73% with the period’s ATR at 0.0937. The stock’s 9-day MACD Oscillator is pointing at -0.0022 and -0.0475 on the 14-day charts.
In the most recent analyst report for vTv Therapeutics Inc. (NASDAQ: VTVT), H.C. Wainwright launched coverage with a Buy rating. Analysts offering their rating for VTVT stock have a consensus rating for the stock as Buy. Currently, 0 brokerage advisors rate VTVT as a “sell,”, while 0 advise that investors “Hold.” 0 analysts have rated the stock as underweight. 0 rates the stock as overweight while 2 have offered a “buy” rating.
What is VTVT’s price target for the next 12 months?
Analysts have a consensus price target ranging from a low of $6.00 and a high of $7.50, with their median price target at $6.75. Looking at these predictions, the average price target given by analysts is for vTv Therapeutics Inc. (VTVT) stock is $6.75.